SAN DIEGO--(BUSINESS WIRE)--Jan. 11, 2006--Inovio Biomedical Corporation (AMEX:INO), a late stage developer of cancer and other therapies using electroporation to deliver drugs and nucleic acids, announces that its subsidiary, Genetronics, Inc., was recently granted two significant patents relating to the use of electroporation to deliver useful therapeutic agents in humans. U.S. patent 6,958,060, entitled, “Method for Muscle Delivery of Drugs, Nucleic Acids and Other Compounds” substantially broadens the company’s claims over in vivo electroporation of muscle tissue and consequently the protectable monopoly for electroporation of muscle tissue.
